ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Forte Medical National Survey Announcement
LONDON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- UK based Medical Technology company…
Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
MILAN, July 17, 2025 /PRNewswire/ --Â A recently published five-year pharmacovigilance study confirms…
MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics
— Milestone Achieved Through Growing Clinical Evidence Demonstrating Real-World Impact on Infection…
